Business Context and Reporting Period
Company: Liquidia Corporation (LQDA)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Liquidia is a biopharmaceutical company focused on respiratory and vascular diseases, specifically pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company generates revenue through the commercialization of YUTREPIA (treprostinil inhalation powder), approved by the FDA in May 2025 and launched in June 2025, and through a promotion agreement with Sandoz for generic Treprostinil Injection. The company is also developing L606, a liposomal formulation of treprostinil.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Total Revenue | $158,320 | $13,996 |
| - Product Sales (YUTREPIA) | $148,288 | $0 |
| - Service Revenue (Treprostinil Injection) | $10,032 | $13,996 |
| Net Loss | $(68,924) | $(128,291) |
| Operating Loss | $(51,376) | $(121,294) |
| Research & Development Expenses | $39,276 | $47,842 |
| Selling, General & Administrative Expenses | $157,178 | $81,569 |
| Cash and Cash Equivalents (Dec 31, 2025) | $190,680 | $176,479 |
| Long-Term Debt (HCR Agreement) | $191,341 | $113,284 |
| Accumulated Deficit | $(626,313) | $(557,389) |
Material Changes vs. Prior Period
- Revenue Surge: Total revenue increased 1,031% year-over-year, driven entirely by the commercial launch of YUTREPIA, which generated $148.3 million in product sales in 2025 compared to zero in 2024.
- Service Revenue Decline: Service revenue from the Sandoz promotion agreement decreased 28% to $10.0 million, attributed to lower sales volumes of Treprostinil Injection.
- Expense Growth: Selling, General, and Administrative (SG&A) expenses increased 93% to $157.2 million, primarily due to higher personnel costs, stock-based compensation, and commercialization expenses for YUTREPIA.
- Improved Loss Profile: Net loss narrowed by 46% to $68.9 million, despite increased operating expenses, due to the significant revenue contribution from YUTREPIA.
- Debt Increase: Long-term debt increased significantly due to additional funding tranches under the HealthCare Royalty Partners (HCR) agreement, totaling $191.3 million as of year-end.
Guidance, Outlook, Risks, and Contingencies
Outlook and Management Commentary
Management believes the company has sufficient cash and cash equivalents to fund operations and meet minimum cash covenants for at least the next twelve months. The company is focused on scaling the commercialization of YUTREPIA and advancing the clinical development of L606, which is currently in a global pivotal study for PH-ILD. Management expects to incur significant expenses in the foreseeable future to support these activities.
Material Risks and Contingencies
- United Therapeutics Litigation: The company faces multiple lawsuits from United Therapeutics regarding patent infringement (specifically the '327 and '782 patents) and trade secret misappropriation. United Therapeutics is seeking injunctive relief that could require YUTREPIA to be removed from the market or have the PH-ILD indication removed. Trial for the '327 Patent Litigation concluded in June 2025, with a decision pending. An adverse outcome could materially disrupt business.
- Supply Chain Constraints: Sales of Treprostinil Injection are constrained by the limited availability of the CADD-MS 3 infusion pump, which is no longer manufactured or supported by ICU Medical. The company is working to identify a replacement pump, but FDA clearance is uncertain.
- Regulatory and Market Risks: Success depends on maintaining FDA approval for YUTREPIA, achieving market acceptance, and securing third-party payor coverage. The company also faces competition from United Therapeutics' Tyvaso DPI and other emerging therapies.
- Debt Covenants: The HCR Agreement requires the company to maintain a minimum cash balance of $15.0 million. Failure to meet covenants could result in acceleration of debt payments.
Key Facts for Investor Verification
- YUTREPIA Commercialization Status: Verify the actual sales trajectory and market penetration of YUTREPIA post-launch (June 2025) against internal forecasts.
- Litigation Outcomes: Monitor the pending court decision in the '327 Patent Litigation and the status of the '782 Patent Litigation, as an injunction could halt revenue generation.
- Infusion Pump Availability: Confirm the timeline for FDA clearance of a replacement infusion pump for Treprostinil Injection to assess the sustainability of service revenue.
- Cash Burn and Runway: Assess the company's ability to maintain the $15.0 million minimum cash covenant under the HCR agreement given the high SG&A spend and ongoing R&D costs.
- L606 Clinical Progress: Track the enrollment and data readouts from the global pivotal study for L606, which is critical for future pipeline valuation.